400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2600115926
尚未开始
/
/
/
2026-01-04
/
/
Central Obesity
An innovative approach to combine intermittent dieting (INTD) with high-intensity interval exercise (HIIE) for curbing central obesity: A comparative randomized controlled trial
An innovative approach to combine intermittent dieting (INTD) with high-intensity interval exercise (HIIE) for curbing central obesity: A comparative randomized controlled trial
The proposed study aims to investigate the effects of high-intensity interval exercise (HIIE) and an intermittent diet (INTD) separately and their combined effects in physically inactive adults with central obesity.
随机平行对照
其它
Participants will be randomised by an independent research assistant using a computer-based random number generator.
Participants were not informed of the specific hypothesis of the study, but due to the nature of the intervention, participants and instructors cannot be blinded. The assessors will be blinded to the group allocation during the evaluation of the indicators before, during, and after the intervention.
Health and Medical Research Fund
/
25
/
2026-01-05
2026-12-31
/
The target population of the proposed study will be physically inactive middle-aged adults (aged 40–64 years) with central obesity in Hong Kong. This particular age group is chosen as the prevalence of central obesity generally increased with age according to the Population Health Survey 2020-22 (2). Physical inactivity will be defined as having less than 3 days of 30-minute moderate-intensity physical activity per week and will be objectively assessed using a device-based measure (i.e. activPAL accelerometer) (3). Central obesity is defined as having a waist circumference 90 centimeters (cm) or above for men and 80 cm or above for women (2). Furthermore, a waist-to-hip ratio at 0.90 or above for men and 0.85 for women also signify centrally obese.;
请登录查看Participants who are not centrally obese will be excluded.;
请登录查看The Chinese University of Hong Kong
/
浙江道尔生物科技有限公司2026-04-16
新药创始人2026-04-16
丁香园 Insight 数据库2026-04-16
2021至2023年理赔服务2026-04-16
干细胞与外泌体2026-04-16
细胞与基因治疗领域2026-04-16
北京药研汇2026-04-16
正大天晴药业集团2026-04-16
复融生物2026-04-16
先通医药2026-04-16